Arrowhead’s ARO-C3 Kidney Trial Reaches Completion, Setting Up the Next Catalyst for ARWR Investors

Arrowhead Pharmaceuticals, Inc. (ARWR) announced an update on their ongoing clinical study.

The Phase 1/2a study “A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and/or Pharmacodynamics of ARO-C3 in Adult Healthy Volunteers and in Adult Patients With Complement-Mediated Renal Disease” tests Arrowhead’s ARO-C3 in kidney disorders driven by the complement system. It aims to show basic safety and early activity in rare renal diseases, which can support future, higher-value trials and partnerships.

The main treatment is ARO-C3, a drug given as a shot under the skin. It is designed to lower overactivity in the complement system, which is linked to C3 glomerulopathy and IgA nephropathy, while a saline placebo is used as a control in healthy volunteers.

The study is interventional and dose-escalating, with both Phase 1 and Phase 2 parts. Healthy volunteers are randomized to receive ARO-C3 or placebo under blinded conditions, while patients with kidney disease later receive open-label ARO-C3 to assess safety and early benefit.

In Part 1, four groups of healthy adults receive one or two doses of ARO-C3 or placebo in a blinded, randomized setup. In Part 2, adults with C3 glomerulopathy or IgA nephropathy receive three open-label doses of ARO-C3, with dose levels based on safety and activity data from the first part.

The trial was first submitted on 8 October 2021, marking the start of clinical development for this program in complement renal disease. As of the last update on 19 May 2026, the study is listed as completed, which means Arrowhead now has key early data that can inform next steps, including larger efficacy trials.

Primary completion indicates core safety and early activity data are in hand, though detailed results have not yet been posted. Full study completion supports a more mature data package that can be used in regulatory talks, partnering discussions, and investor updates over the coming quarters.

For Arrowhead’s stock, a completed early-stage study in a high-value renal niche can be a mild positive catalyst, especially if the market expects clean safety and consistent biomarker signals. Investors will watch for any sign that ARO-C3 can offer a more convenient or safer option versus existing complement drugs, which could expand Arrowhead’s value beyond liver-focused programs.

Competitors in complement-mediated diseases include established players with approved therapies and several biotech peers targeting C3 or related pathways. Strong ARO-C3 data could shift sentiment toward Arrowhead as a potential partner or acquisition target, while weak or mixed data may increase focus on the firm’s other pipeline assets.

The ARO-C3 study has been completed and recently updated on the registry, and further details are available on the ClinicalTrials portal.

To learn more about ARWR’s potential, visit the Arrowhead Pharmaceuticals, Inc. drug pipeline page.